Andris Kazaks

Dr. Andris Kazaks

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2020 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
Nikita ZrelovsNikita Zrelovs
Nikita Zrelovs
ADAndris Dislers
Andris Dislers
AKAndris Kazaks
Andris Kazaks
The first complete genome that was sequenced at the beginning of the sequencing era was that of a phage, since then researchers throughout the world have been steadily describing and publishing genomes from a wide array of phages, uncovering the secrets of the most abundant and diverse biological entities known to man. Currently, we are experiencing an unprecedented rate of novel bacteriophage discovery, which can be seen from the fact that the amount of complete bacteriophage genome entries in public sequence repositories has more than doubled in the past 3 years and is steadily growing without showing any sign of slowing down. The amount of publicly available phage genome-related data can be overwhelming and has been summarized in literature before but quickly becomes out of date. Thus, the aim of this paper is to briefly outline currently available phage diversity data for public acknowledgment that could possibly encourage and stimulate future “depth” studies of particular groups of phages or their gene products.

14 November 2008 in Biotechnology Journal
Verified
Journal Article
Closed access
PDF file
AKAndris Kazaks
Andris Kazaks
RBReinis Balmaks
Reinis Balmaks
TVTatyana Voronkova
Tatyana Voronkova
VOVelta Ose
Velta Ose
PPPaul Pumpens
Paul Pumpens

2 December 2013 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
RBReinis Balmaks
Reinis Balmaks
IRIrina Ribakova
Irina Ribakova
DGDace Gardovska
Dace Gardovska
AKAndris Kazaks
Andris Kazaks

10 November 2017 in BMC Biotechnology
Verified
Journal Article
Open access
PDF file
AKAndris Kazaks
Andris Kazaks
ILI-Na Lu
I-Na Lu
SFSophie Farinelle
Sophie Farinelle
ARAlex Ramirez
Alex Ramirez
VCVincenzo Crescente
Vincenzo Crescente
WRWilliam M. Rosenberg
William M. Rosenberg
The lack of a universal influenza vaccine is a global health problem. Interest is now focused on structurally conserved protein domains capable of eliciting protection against a broad range of influenza virus strains. The long alpha helix (LAH) is an attractive vaccine component since it is one of the most conserved influenza hemagglutinin (HA) stalk regions. For an improved immune response, the LAH domain from H3N2 strain has been incorporated into virus-like particles (VLPs) derived from hepatitis B virus core protein (HBc) using recently developed tandem core technology. Fermentation conditions for recombinant HBc-LAH were established in yeast Pichia pastoris and a rapid and efficient purification method for chimeric VLPs was developed to match the requirements for industrial scale-up. Purified VLPs induced strong antibody responses against both group 1 and group 2 HA proteins in mice. Our results indicate that the tandem core technology is a useful tool for incorporation of highly hydrophobic LAH domain into HBc VLPs. Chimeric VLPs can be successfully produced in bioreactor using yeast expression system. Immunologic data indicate that HBc VLPs carrying the LAH antigen represent a promising universal influenza vaccine component.

14 November 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ECElina Cernooka
Elina Cernooka
JRJanis Rumnieks
Janis Rumnieks
KTKaspars Tars
Kaspars Tars
AKAndris Kazaks
Andris Kazaks
Modern DNA sequencing capabilities have led to the discovery of a large number of new bacteriophage genomes, which are a rich source of novel proteins with an unidentified biological role. The genome of Enterobacter cancerogenus bacteriophage Enc34 contains several proteins of unknown function that are nevertheless conserved among distantly related phages. Here, we report the crystal structure of a conserved Enc34 replication protein ORF6 which contains a domain of unknown function DUF2815. Despite the low (~15%) sequence identity, the Enc34 ORF6 structurally resembles the gene 2.5 protein from bacteriophage T7, and likewise is a single-stranded DNA (ssDNA)-binding protein (SSB) that consists of a variation of the oligosaccharide/oligonucleotide-binding (OB)-fold and an unstructured C-terminal segment. We further report the crystal structure of a C-terminally truncated ORF6 in complex with an ssDNA oligonucleotide that reveals a DNA-binding mode involving two aromatic stacks and multiple electrostatic interactions, with implications for a common ssDNA recognition mechanism for all T7-type SSBs.

23 March 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ECElina Cernooka
Elina Cernooka
JRJanis Rumnieks
Janis Rumnieks
Nikita ZrelovsNikita Zrelovs
Nikita Zrelovs
KTKaspars Tars
Kaspars Tars
AKAndris Kazaks
Andris Kazaks
Endolysins are bacteriophage-encoded peptidoglycan-degrading enzymes with potential applications for treatment of multidrug-resistant bacterial infections. Hafnia phage Enc34 encodes an unusual endolysin with an N-terminal enzymatically active domain and a C-terminal transmembrane domain. The catalytic domain of the endolysin belongs to the conserved protein family PHA02564 which has no recognizable sequence similarity to other known endolysin types. Turbidity reduction assays indicate that the Enc34 enzyme is active against peptidoglycan from a variety of Gram-negative bacteria including the opportunistic pathogen Pseudomonas aeruginosa PAO1. The crystal structure of the catalytic domain of the Enc34 endolysin shows a distinctive all-helical architecture that distantly resembles the α-lobe of the lysozyme fold. Conserved catalytically important residues suggest a shared evolutionary history between the Enc34 endolysin and GH73 and GH23 family glycoside hydrolases and propose a molecular signature for substrate cleavage for a large group of peptidoglycan-degrading enzymes.